Board Changes

Oxford Biomedica PLC

18 November 2024

 

Board Changes

-     Appointment of Colin Bond, a highly experienced Board member and Audit Committee Chair with extensive international CDMO and biopharma expertise

-     Appointment made as part of OXB's Board succession planning

Oxford, UK - 18 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Colin Bond as a Non-Executive Director effective 1 January 2025. Mr. Bond will also join the Audit Committee as part of succession planning ahead of Stuart Henderson losing his independent status as a Non-Executive Director in June 2025.

Colin Bond has a wealth of international experience in the CDMO and biopharma industries and was most recently Chief Financial Officer of Sandoz listed on the SIX Swiss Exchange, where he played a key role in the company's successful spin-off from Novartis. Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma and Evotec. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange, for ten years until May 2023. He is currently Chair of the Audit Committee of BioPharma Credit PLC on the London Stock Exchange and a member of the Supervisory Board of Formycon AG. 

During his early career, Mr. Bond worked as a pharmacist, auditor and management consultant for Procter & Gamble, Arthur Andersen and PwC. Mr. Bond is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. He holds a BSc in Pharmacy from Aston University and an MBA from London Business School.

Additionally, OXB announces that Leone Patterson has informed the Board of her decision to step down as a Non-Executive Director on 31 December 2024 in order to focus on her new responsibilities following her recent appointment as Chief Business and Financial Officer of Zymeworks.

Dr. Roch Doliveux, Chair of OXB, commented: "Colin is a highly strategic operator with extensive international CDMO and healthcare sector expertise plus first-rate technical accounting credentials. He is well regarded by the investment community and has overseen organisations that have undergone significant growth and transformation. On behalf of the Board, I am delighted to welcome Colin to OXB and thoroughly look forward to working with him. I would also like to thank Leone for her sharp analytical insights and active contributions to OXB during her tenure on the Board and wish her the very best with her new responsibilities."

Colin Bond, incoming Board member at OXB, said: "OXB's position as a leader in cell and gene therapy manufacturing, combined with its innovative approach and strong client partnerships, presents a compelling opportunity that I have recently watched with interest. I am excited to join the Board at this important time and look forward to working with the team to support OXB's continued growth and success in enabling the delivery of life-changing therapies to patients worldwide."

Relevant disclosures 

Save as disclosed, there are no disclosures required to be made in accordance with UKLR 6.4.8(R).

-Ends-

Enquiries:       

OXB:

Sophia Bolhassan, Head of Investor Relations - T: [phone] / E: [e-mail]

ICR Healthcare:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

END